10-Q · May 12, 2026
Passage Bio's Q1 2026 10-Q report indicates a continued focus on clinical development with significant workforce reductions aimed at cost management. The company reported a narrowed net loss of $7.6 million, improved…
Earnings analysis · 10-Q
PASG earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q does not include the income statement, balance sheet, cash-flow statement, or segment disclosures, so revenue, margins, EPS, free cash flow, and period-over-period trends cannot be assessed from the…
Read full summary
The extracted 10-Q does not include the income statement, balance sheet, cash-flow statement, or segment disclosures, so revenue, margins, EPS, free cash flow, and period-over-period trends cannot be assessed from the filing text provided. The principal development is the proposed Remix Merger, anticipated in Q4 2026, alongside approximately $100.0 million of financing, but current Passage Bio stockholders are expected to retain only approximately 6% of the combined company. Liquidity remains a major concern: cash was approximately $24.2 million at June 30, 2026, and management disclosed substantial doubt about continuing as a going concern within one year.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls remained effective
Management reported that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026.
-
Workforce restructuring completed
The company implemented a restructuring plan that reduced its workforce by 75% during the quarter, which management expects to modify control responsibilities and review procedures without materially affecting internal controls.
-
Merger targeted for Q4 2026 close
The proposed Merger is anticipated to close in the fourth quarter of 2026, subject to customary closing conditions.
-
Proposed merger includes $100 million financing
The concurrent financing is expected to provide approximately $100.0 million, while former Remix securityholders and financing investors are expected to own approximately 65% and 29% of the combined company, respectively.
What to watch
-
Merger completion remains uncertain
The Merger is subject to closing conditions and is only anticipated to close in the fourth quarter of 2026. If it is not completed, the company states that its stock price could decline significantly; the agreement may be terminated if the Merger is not completed by December 24, 2026, subject to extension provisions.
-
Significant dilution and transaction costs
Immediately before the Merger, current Passage Bio stockholders are expected to own approximately 6% of the combined company, compared with approximately 65% for former Remix securityholders and 29% for concurrent financing investors. The company may also owe Remix a nonrefundable $1.5 million termination fee in specified circumstances.
-
Going-concern uncertainty
The company disclosed substantial doubt about its ability to continue as a going concern within one year after the financial statements are issued. Cash and cash equivalents were approximately $24.2 million as of June 30, 2026, and management stated that the company has sustained recurring operating losses and used cash in operations.
Management's outlook
No numeric revenue or EPS guidance was provided in the extracted 10-Q. Management states that the Merger is anticipated to close in the fourth quarter of 2026, assuming satisfaction or waiver of closing conditions.
Earlier filings 4
10-K · March 3, 2026
Passage Bio’s 2025 Form 10-K emphasizes progress advancing its lead gene therapy PBFT02 (AAV1, ICM delivery) for FTD-GRN with durable CSF PGRN increases and expansion into FTD-C9orf72 cohorts, while continuing…
10-Q · August 12, 2025
Passage Bio reported a materially smaller Q2 2025 loss: net loss of $9,385 (EPS $(2.96)) vs $15,991 (EPS $(5.09)) in Q2 2024, driven by sharp cuts to R&D and G&A. Cash and cash equivalents rose to $57,626 as of June 30,…
10-Q · August 8, 2024
Passage Bio reported improved operating results in Q2 2024 with a net loss of $15.99M (EPS -$0.26) compared with a net loss of $23.86M (EPS -$0.44) in Q2 2023. Operating expenses declined (R&D $10.43M, G&A $6.51M) and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.